Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyHighmark Blueshield Neny Hemophilia Prior Auth | O…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Hemophilia / Bleeding Disorder Medication Prior Authorization Form Coverage Criteria

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers prior authorization documentation and clinical criteria required for authorization of hemophilia and bleeding-disorder therapies for Highmark Blue Shield members; affects prescribing providers requesting coverage for factor products and related medications.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyHemophilia / Bleeding Disorder Medication Prior Authorization Form Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a separate, fully completed prior authorization form with required clinical documentation and provider signature via fax to 1-866-240-8123 or mail to SPECARE, 120 Fifth Avenue, Pittsburgh, PA 15222.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    severe <1%Severe baseline factor
    moderate 1%-5%Moderate baseline factor

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    mild 5-40%Mild baseline factor
    1-866-240-8123Fax
    SPECARE PittsburghMail

    Coverage and Medical Necessity Criteria

    Clinical documentation required for authorization

    Authorization is assessed using completed clinical criteria fields when ALL of the following are documented

    Required documentation: Diagnosis code and description must be provided

    from form header

    Factor level: Baseline factor level (%) must be provided and categorized (mild/moderate/severe)mild 5-40%; moderate 1-5%; severe <1%

    used for dosing and severity assessment

    Weight: Member actual body weight (ABW) and date measured must be provided for dose calculations

    form asks whether dose calculated using ABW or IBW

    Inhibitor status: Past history of inhibitor development and current inhibitor presence with Bethesda units must be documented

    Indicate if member underwent immune tolerance induction and outcome (success/failed)

    Therapy intent: Type of therapy must be specified (On-Demand/Prophylaxis/Perioperative)

    Form also asks if member is a candidate for prophylactic therapy and if a management strategy is in place

    Prior therapies: Alternatives tried and documentation of failure of therapy should be provided (up to two prior drugs)

    Form requests drug name, strength, dose, directions, type of therapy, and failure documentation

    Reauthorization/Response: For reauthorization, documentation that member is stable on therapy and any bleeding episodes during therapy are documented (occurrence and type)

    Form asks whether condition is stable and whether bleeding episodes occurred with details

    The form itself does not list additional or separate coverage criteria beyond the clinical fields it requests. Authorization decisions are based on the completion of the form’s required clinical information (diagnosis, baseline factor level, weight, inhibitor history, therapy intent, prior therapies and supporting documentation).

    The form contains no explicit statements enumerating conditions that are "not medically necessary." It does, however, state that the provider certifies the information is true and that payment is subject to member eligibility and that authorization does not guarantee payment.

    Coding and Clinical Definitions

    No codes listed on formmixed
    No codes listed
    Baseline factor level categories — mild/moderate/severe definitions
    Mild baseline factor level5%–40% baseline factor level
    Moderate baseline factor level1%–5% baseline factor level
    Severe baseline factor level<1% baseline factor level

    Provider Submission Requirements and Actions

    Prior Authorization

    Prior Authorization Submission Requirements

    Prior authorization is required. Submit the completed prior authorization form with all supporting clinical documentation, including diagnosis, baseline factor level, inhibitor status (current or past), Bethesda units if applicable, body weight and date measured, and any relevant treatment history.

    • Fax completed form and all clinical documentation to 1-866-240-8123
    • Or mail to: 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222
    Documentation Required

    Alternatives Tried and Failure Documentation

    The form collects prior therapies tried, details (drug name, strength, dose, directions), type of therapy, and documentation of failure. It also asks whether the member is a candidate for prophylactic therapy, whether a management strategy is in place, and requests reauthorization stability and bleed documentation when applicable.

    • List each prior medication trial with dose, dates, and reason for failure

    Background and Purpose

    This form is intended to support prior authorization decisions for treatment of bleeding disorders by capturing the clinical details used to assess medical necessity and dosing. Required information includes diagnosis and description, disease severity and baseline factor level, member weight and measurement date for dose calculations, inhibitor history and Bethesda measurements, type/intent of therapy (on‑demand, prophylaxis, perioperative), prior therapies and failure documentation, and the medical rationale/treatment plan.

    Definitions and Clinical Measures

    Baseline factor level categories — mild (5-40%), moderate (1%-5%), severe (<1%)
    Mild5%–40%
    Moderate1%–5%
    Severe<1%
    Bethesda Units (BU) — inhibitor quantification measure
    Bethesda Units (BU)Laboratory measure used to quantify inhibitor titer (documented on form as 'Bethesda Units (BU)')
    Inhibitor presenceForm requests whether an inhibitor is currently present and, if yes, the BU value
    Historical inhibitor data
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyHemophilia / Bleeding Disorder Medication Prior Authorization Form Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a separate, fully completed prior authorization form with required clinical documentation and provider signature via fax to 1-866-240-8123 or mail to SPECARE, 120 Fifth Avenue, Pittsburgh, PA 15222.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Clinical DefinitionsProvider Submission Requirements and ActionsBackground and PurposeDefinitions and Clinical Measures
  1. Indicate candidacy for prophylactic therapy and provide supporting documentation
  2. Documentation Required

    One Form Per Medication

    Submit one fully completed form for each medication requested. Ensure member demographics, provider information (including physician name, NPI/Tax ID, address), medication information (name, strength, dose, directions, type of therapy, quantity, refills, shipping preference), and signature/date are included.

    • Complete ALL information on the form; print/type legibly in blue or black ink
    • Prescribing physician should complete the form in most cases
    • Include physician address as required for notification
    Note

    Payment and Eligibility Notice

    Payment is subject to member eligibility at the time of claim; an authorization or approval does not guarantee payment.

    • Authorization only indicates medical review approval and is not a guarantee of payment or coverage
    Form asks about past history of inhibitor development and results of Immune Tolerance Induction (success/failed)